- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07660510
Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches (CAPSASENS)
The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Category 2 Study (Interventional Research with Minimal Risks and Constraints), monocentric, uncontrolled, non-randomized, open-label and prospective.
This study involves conducting tests and questionnaires before and 1 month after the application of a patch administered as part of standard clinical practice.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Amélie LEVESQUE, MD
- Numéro de téléphone: +33240083912
- E-mail: amelie.levesque@chu-nantes.fr
Lieux d'étude
-
-
-
Nantes, France
- Nantes University Hospital
-
Contact:
- Nantes University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men or women ≥ 18 years old.
- Patients suffering from chronic pelvi-perineal neuralgia (>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).
- Patient who has never been treated with an 8% capsaicin patch for this indication.
- Patients who have signed the informed consent form for the study at the inclusion visit.
- Women must meet one of the following criteria at the time of inclusion:
- Use adequate contraceptive measures;
- or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);
- or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;
- or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.
Exclusion Criteria:
- Patients under guardianship, curatorship, or legal protection.
- Pregnant or breastfeeding women.
- Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.
- Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).
- Patients not affiliated with the French Social Security system.
- Patients with insufficient cooperation and/or understanding to strictly comply with the protocol requirements.
- Patients who have taken analgesics within the 12 hours prior to measurements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pain sensitization parameter testing
Pre-inclusion visit (routine care consultation): Verification of inclusion and exclusion criteria. Inclusion visit (Day 0): Consent signing, questionnaires (ConvergencePP Score/Central Sensitization Inventory, DN4), and a series of tests, followed by the application of the high-concentration capsaicin patch (PCHC) (performed during routine care). Day 30 visit (+7 days): Questionnaires (same as V1 + PGI-c) and a series of tests. |
Quantitative Sensory Testing and questionnaires |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Composite criterion
Délai: Difference between Day 0 and Day 30
|
Composite criterion constructed from a Principal Component Analysis including the differences between Day 0 (before patch application) and Day 30 in pain perception thresholds (to cold, heat, pressure, and mechanical stimulation) in both the area treated with the high-concentration capsaicin patch and the corresponding dermatome, as well as the change in the pain receptive field area in the treated zone and the area under the curve of temporal summation measurements. |
Difference between Day 0 and Day 30
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (1)
Délai: Between before and 30 days after patch application
|
Difference in pressure pain thresholds in the treated area |
Between before and 30 days after patch application
|
|
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (2)
Délai: Between before and 30 days after patch application
|
Difference in mechanical stimulation pain thresholds |
Between before and 30 days after patch application
|
|
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (3)
Délai: Between before and 30 days after patch application
|
Difference in cold pain thresholds in the treated area |
Between before and 30 days after patch application
|
|
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (4)
Délai: Between before and 30 days after patch application
|
Difference in heat pain thresholds in the treated area |
Between before and 30 days after patch application
|
|
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (5)
Délai: Between before and 30 days after patch application
|
Difference in pain receptive field area |
Between before and 30 days after patch application
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (1)
Délai: Between before and 1 month after patch application.
|
Difference in pressure pain thresholds in an area of the dermatome not directly treated by the patch:
|
Between before and 1 month after patch application.
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (2)
Délai: Between before and 1 month after patch application.
|
Difference in mechanical stimulation pain thresholds in an area of the dermatome not directly treated by the patch |
Between before and 1 month after patch application.
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (3)
Délai: Between before and 1 month after patch application.
|
Difference in cold pain thresholds in an area of the dermatome not directly treated by the patch. |
Between before and 1 month after patch application.
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (4)
Délai: Between before and 1 month after patch application.
|
Difference in heat pain thresholds in an area of the dermatome not directly treated by the patch. |
Between before and 1 month after patch application.
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (5)
Délai: Between before and 1 month after patch application.
|
Difference in the area under the curve of temporal summation measurements in the treated area |
Between before and 1 month after patch application.
|
|
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (6)
Délai: Between before and 1 month after patch application.
|
Difference in the duration of pain persistence after the end of temporal summation (in seconds). |
Between before and 1 month after patch application.
|
|
Measure the patient's therapeutic response to the treatment
Délai: Day 30
|
Patient Global Impression of Change (PGI-C). The therapeutic response is defined as a patient who scores 1 to 3 on the PGI-C. |
Day 30
|
|
Evaluate the predictive value of temporal summation with regard to the therapeutic response to the high-concentration capsaicin patch
Délai: Between before and 1 month after patch application.
|
Investigation of a relevant threshold for temporal summation to predict the therapeutic response. Quantification of the positive predictive value. |
Between before and 1 month after patch application.
|
|
Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data
Délai: Between before and 1 month after patch application
|
Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data. The Convergences PP score is a clinical questionnaire used to diagnose sensitization in the pelvic region. A score is considered positive from 5/10 (sensitivity = 95%, specificity = 87%). The Central Sensitization Inventory (CSI) is a self-administered questionnaire used to diagnose central sensitization. A score is considered positive from 40/100. Correlations between the Convergences PP score, CSI, and semi-objective sensitization data (pain thresholds and temporal summation) will be measured using Spearman's correlation coefficient to explore the relationships between these variables. |
Between before and 1 month after patch application
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies du système nerveux
- Maladies neuromusculaires
- Maladies du système nerveux périphérique
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Névralgie
- Douleur nociplasique
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Méthodes épidémiologiques
- Collecte de données
- Mécanismes d'évaluation des soins de santé
- Qualité des soins de santé
- Santé publique
- Environnement et santé publique
- Enquêtes et questionnaires
Autres numéros d'identification d'étude
- RC25_0536
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .